463 NG2-CAR-Macrophages Demonstrate Robust Anti-Tumor Effects in Glioblastoma Models
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
INTRODUCTION: The immunosuppressive tumor microenvironment of glioblastoma, comprised of tumor-associated macrophages, poses a significant challenge for designing therapeutics. Chimeric antigen receptor (CAR) technology is a cellular immunotherapy, currently being explored in T cells in Phase 1 clinical trials, that engineers a patient’s immune cells to target and kill cancer cells, overcoming the immunosuppressive microenvironment. CAR-Macrophages (CAR-M) offer a novel application of this technology by leveraging the macrophage-rich microenvironment while also offering an adaptive function CAR-T cells lack. METHODS: Using primary human macrophages, we have designed NG2-CAR-Ms to recognize and phagocytose glioblastoma cells. The CAR contains an extracellular single-chain variable fragment (scFv) that binds NG2 and an FcR gamma intracellular domain to trigger phagocytosis and allow for downstream analysis. We utilized glioblastoma spheroid models to perform spheroid adhesion, invasion, phagocytosis, cell death, and tumor spheroid growth assays in vitro. For the in vivo portions of this study, we utilized PDX mouse models for tumor growth and survival studies. RESULTS: We have demonstrated that NG2-CAR-Ms phagocytosis glioblastoma cells and inhibited tumor spheroid growth in a target-specific manner. Our in vivo studies demonstrated decreased tumor volumes in mice injected with NG2-CAR-Ms compared to controls. Together, these results suggest that NG2-CAR-Ms impede the growth of glioblastoma cells in vitro and in vivo, directly through phagocytosis and tumor cell death. CONCLUSIONS: CAR-Macrophages are a new technology currently under-explored in glioblastoma. Our study suggests NG2-CAR-Ms have robust anti-tumor effects in in vitro and in vivo models of glioblastoma. Further work is underway exploring the ability of NG2-CAR-Ms to further educate the adaptive immune response in glioblastoma.
Fields of Study & Subjects
Glioma Diagnosis and Treatment
CAR-T cell therapy research
Immune cells in cancer
Publication details
- Journal / source
- Neurosurgery
- Volume
- 72
- Issue
- Supplement_1
- Pages
- 135–136
- Publication date
- 26 March 2026
- Language
- EN